Skip to main content

Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation

Buy Article:

$51.00 plus tax (Refund Policy)


Summary Background 

Overexpression of cyclooxygenase-2 (COX-2), resulting in excessive prostaglandin production, has been observed in human epidermal keratinocytes after ultraviolet B injury, in squamous cell skin carcinoma (SCC), in actinic keratoses, and in the early stages of carcinogenesis in a wide variety of tissues. The dysregulation of COX-2 expression can in part be due to functional changes affecting regulatory elements in the promoter or 3′ untranslated region (UTR) of the gene. Two common polymorphisms (–765G→C, and –1195A→G) in the promoter region of the COX-2 gene (now PTGS2), and one common polymorphism in the 3′ UTR (8473T→C) have been described, and reported as associated with various malignancies. Objectives 

To determine if common known polymorphisms in the regulatory region of the COX-2 gene (PTGS2) can be associated with nonmelanoma skin cancer (NMSC) predisposition after organ transplantation, to evaluate if cancer risks are associated with specific COX-2 gene (PTGS2) haplotypes containing these polymorphisms, and to identify possible new genetic polymorphisms in the proximal 5′ or 3′ regulatory regions of the gene associated with disease. Methods 

The frequency of the three polymorphisms was determined in 240 Northern Italian transplant recipient patients (107 cases and 133 controls) with polymerase chain reaction–restriction fragment length polymorphism analysis. The proximal 5′ and 3′ regulatory regions of the gene were screened by heteroduplex analysis. Results 

Stratification by age at transplant and type of tumours [SCC or basal cell carcinoma (BCC)] demonstrated that allele –765C represented a protective factor in BCC cases undergoing transplantation before 50 years of age (CC + CG vs. GG, Fisher exact test P = 0·003). One rare polymorphism, −62C→G, was detected in the 5′ flanking region. The allele frequency of –62G was 0·019, and no difference in genotype between cases and controls was observed. No other variants were found, suggesting that sequence variations in these regions are not likely to contribute to NMSC risk in this population. Haplotype analysis showed that the haplotype containing all major alleles represents a protective factor in patients with SCC undergoing transplantation after 50 years of age [P = 0·009; OR = 0·37 (0·18–0·79)] and that variant –1195A→G may represent a risk factor in this subgroup of patients [P = 0·01; OR = 4·77 (1·47–16·41)]. Haplotype analysis in patients with BCC revealed that variant –765C might be a protective factor in patients undergoing transplantation before 50 years of age. Variant 8473T→C, located in the 3′ UTR region of the gene, showed no association with NMSC risk after transplantation. Conclusions 

COX-2 common variants –765G→C and –1195A→G appear to be associated with risk of NMSC, although in different ways in the SCC and BCC subgroups, indicating that environmental and genetic risk factors may play different roles in the outcome leading to these two phenotypes.

Keywords: COX-2 gene; PTGS2; nonmelanoma skin cancer; polymorphisms; transplantation

Document Type: Research Article


Affiliations: 1: Department of Biomedical and Surgical Sciences, Section of Dermatology and Venereal Diseases, University of Verona, Verona, Italy 2: Centro Studi Gruppo Italiano di Studi Epidemiologici in Dermatologia, Bergamo, Italy 3: Department of Nephrology, Ospedali Riuniti di Bergamo, Bergamo, Italy 4: Kidney Transplantation Center, University of Verona, Verona, Italy 5: Division of Cardiac Surgery, University of Verona, Verona, Italy 6: Department of Nephrology, University of Verona, Verona, Italy 7: Department of Dermatology, University of Padua, Padua, Italy

Publication date: July 1, 2007


Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more
Real Time Web Analytics